Imagine a cancer vaccine designed for you, and you alone. What once sounded like science fiction is moving closer to reality, offering fresh hope to patients worldwide.
On 22 October 2026, pharmaceutical companies announced encouraging findings from research into a personalised cancer vaccine. Developed using the unique features of an individual’s tumour, the vaccine aims to train the body’s natural defences to recognise and destroy cancer cells, according to the study of the American Journal of Managed Care®.
Unlike conventional vaccines, this one does not prevent cancer. Instead, it is designed to stop the disease from returning after surgery.
Researchers reported that combining the experimental vaccine with an existing cancer medicine reduced the risk of skin cancer returning or causing death by 42 per cent over two years. The findings suggest a future where cancer treatment could be tailored to each patient rather than following the same approach for everyone.
However, the treatment remains experimental, and further scientific assessment is essential before its wider use.
For Bangladesh, the breakthrough raises an uncomfortable question: who will afford such personalised care?
With cancer treatment already financially devastating for many families, individually manufactured vaccines could deepen inequalities between wealthy and poorer nations.
The promise is extraordinary. But its greatest achievement will be ensuring that lifesaving innovation reaches everyone, not merely those who can pay.